priors.science/reviews/colorectal-cancer-targeted-immunotherapy

Colorectal Cancer Targeted Immunotherapy

The current evidence on 10 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

10claims tracked
100primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
7 Established · 2 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Pembrolizumab first-line in microsatellite instability-high metastatic colorectal cancerMsi ImmunoEstablished90%9
RAS mutation predicts no anti-EGFR benefitEGFR RasEstablished90%10
Encorafenib plus cetuximab in BRAF V600E-mutant colorectal cancerBraf HER2Established90%9
Nivolumab plus ipilimumab in microsatellite instability-high colorectal cancerMsi ImmunoEstablished88%9
Adjuvant oxaliplatin-based chemotherapy in stage III colon cancerEarly StageEstablished88%10
Anti-EGFR therapy in left-sided RAS wild-type colorectal cancerEGFR RasEstablished87%13
Neoadjuvant immunotherapy in mismatch repair-deficient colon cancerEarly StageEstablished87%12
Second-line ramucirumab or afliberceptVegf AntiLikely82%10
HER2-targeted therapy in HER2-amplified colorectal cancerBraf HER2Likely80%9
Bevacizumab first-line overall survivalVegf AntiLong-standingUncertain60%10
Track Colorectal Cancer Targeted Immunotherapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.